At a glance
- Originator Guangzhou Saipute Medical Technology Co Ltd
- Class 2 ring heterocyclic compounds; Carboxylic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
- Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation; Pain
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Inflammation in China (Implant) (Guangzhou Saipute Medical Technology Co. Ltd. pipeline, September 2023)
- 12 Sep 2023 Discontinued - Preclinical for Pain in China (Implant) (Guangzhou Saipute Medical Technology Co. Ltd. pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Inflammation in China (Implant)